Particle.news

Download on the App Store

Louisiana Warns After Two Hospitalizations Tied to Unlicensed Botox Injections

State guidance emphasizes use of approved products from qualified providers in licensed healthcare settings.

Overview

  • LDH reports two unrelated severe illnesses in September among Louisiana residents after botulinum toxin injections, with both patients hospitalized.
  • One case involved an unlicensed product purchased online, while the other involved injections by a person of unknown licensure in a non-medical setting.
  • Patients developed botulism-like symptoms within days, including blurry or double vision, drooping eyelids, difficulty swallowing, slurred speech, breathing problems, and muscle weakness.
  • Officials note adverse events reported across the U.S. linked to counterfeit products marketed on social media, including vendors using TikTok for advertising and WhatsApp for transactions.
  • Residents are urged to receive injections only from licensed, trained providers using FDA-approved products from authorized suppliers in licensed or accredited facilities, avoid self-injection, seek urgent care if symptoms arise, and report suspected counterfeit products to the FDA.